{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:35:52Z","timestamp":1786988152113,"version":"build-2736575974"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:00:00Z","timestamp":1658102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017959","name":"Health Commission of Hebei Province","doi-asserted-by":"publisher","award":["20220109"],"award-info":[{"award-number":["20220109"]}],"id":[{"id":"10.13039\/100017959","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008238","name":"Hebei Province Department of Science And Technology","doi-asserted-by":"publisher","award":["192777127D"],"award-info":[{"award-number":["192777127D"]}],"id":[{"id":"10.13039\/501100008238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018806","name":"Science and Technology Department of Hubei Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018806","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.ejps.2022.106266","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T15:10:30Z","timestamp":1658243430000},"page":"106266","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Norvancomycin for the treatment of central nervous system MRSA infections: A randomized controlled trial"],"prefix":"10.1016","volume":"177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3811-0195","authenticated-orcid":false,"given":"Yaqian","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenpeng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuecheng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linhui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weichong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongmao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2022.106266_bib0001","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ncl.2008.03.013","article-title":"Update in the diagnosis and management of central nervous system infections","volume":"26","author":"Ziai","year":"2008","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.ejps.2022.106266_bib0002","first-page":"1530","article-title":"Epidemiology of intracranial infection after craniotomy: a meta-analysis","volume":"28","author":"Wang","year":"2013","journal-title":"West China Med. J."},{"key":"10.1016\/j.ejps.2022.106266_bib0003","doi-asserted-by":"crossref","first-page":"e01608","DOI":"10.1128\/AAC.01608-17","article-title":"Metabolic mitigation of staphylococcus aureus vancomycin intermediate-level susceptibility","volume":"62","author":"Gardner","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2022.106266_bib0004","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the infectious diseases society of America for the experimental of methicillin resistant staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejps.2022.106266_bib0005","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10096-007-0435-9","article-title":"Population pharmacokinetic and pharmacodynamic modeling of norvancomycin","volume":"27","author":"Zhang","year":"2008","journal-title":"Eur. J. Clin. Microbiol."},{"key":"10.1016\/j.ejps.2022.106266_bib0006","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10096-016-2803-9","article-title":"Drug concentrations in the serum and cerebrospinal fluid of patients treated with norvancomycin after craniotomy","volume":"36","author":"Wu","year":"2017","journal-title":"Eur. J. Clin. Microbiol."},{"key":"10.1016\/j.ejps.2022.106266_bib0007","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ijantimicag.2017.01.014","article-title":"Pharmacokinetics and cerebrospinal fluid penetration of norvancomycin in Chinese adult patients","volume":"49","author":"Li","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejps.2022.106266_bib0008","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1586\/eri.09.123","article-title":"Use of vancomycin pharmacokinetic\u2013pharmacodynamic properties in the treatment of MRSA infections","volume":"8","author":"Giuliano","year":"2014","journal-title":"Expert Rev. Anti Infect."},{"key":"10.1016\/j.ejps.2022.106266_bib0009","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ijantimicag.2017.01.002","article-title":"Intrathecal or intraventricular administration of colistin, vancomycin and amikacin for central nervous system infections in neurosurgical patients in an intensive care unit","volume":"49","author":"Tsimogianni","year":"2017","journal-title":"Int. J. Antimicrob. Ag"},{"key":"10.1016\/j.ejps.2022.106266_bib0010","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1086\/425368","article-title":"Practice guidelines for the management of bacterial meningitis","volume":"39","author":"Tunkel","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejps.2022.106266_bib0011","doi-asserted-by":"crossref","first-page":"161","DOI":"10.18433\/J3493F","article-title":"Association between vancomycin blood brain barrier penetration and clinical response in postsurgical meningitis","volume":"20","author":"Wang","year":"2017","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.ejps.2022.106266_bib0012","first-page":"312","article-title":"Determination of vancomycin and norvancomycin in human cerebrospinal fluid by HPLC","volume":"31","author":"Dong","year":"2016","journal-title":"West China J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2022.106266_bib0013","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jaad.2019.02.002","article-title":"Vancomycin-associated drug-Induced hypersensitivity syndrome","volume":"81","author":"Madigan","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.ejps.2022.106266_bib0014","first-page":"694","article-title":"The use of vancomycin with its therapeutic and adverse effects: a review","volume":"19","author":"Bruniera","year":"2015","journal-title":"Eur. Rev. Med. Pharmaco."},{"key":"10.1016\/j.ejps.2022.106266_bib0015","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/cpt.726","article-title":"The nephrotoxicity of vancomycin","volume":"102","author":"Filippone","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2022.106266_bib0016","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1345\/aph.1C145","article-title":"Sensorineural hearing loss associated with intrathecal vancomycin","volume":"37","author":"Klibanov","year":"2003","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejps.2022.106266_bib0017","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.12659\/AJCR.909956","article-title":"Agranulocytosis induced by vancomycin. Case report and literature review","volume":"19","author":"Fonzo","year":"2018","journal-title":"Am. J. Case Rep."},{"key":"10.1016\/j.ejps.2022.106266_bib0018","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/jac\/dkaa414","article-title":"Determination of norvancomycin epidemiological cut-off values (ECOFFs) for Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus and Staphylococcus hominis","volume":"76","author":"Yang","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejps.2022.106266_bib0019","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ajic.2007.07.015","article-title":"Postoperative intracranial neurosurgery infection rates in North America versus Europe: a systematic analysis","volume":"36","author":"Mcclelland","year":"2008","journal-title":"Am. J. Infect. Control"},{"key":"10.1016\/j.ejps.2022.106266_bib0020","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ijantimicag.2013.02.006","article-title":"Intraventricular and intrathecal colistin as the last therapeutic resort for the experimental of multidrug-resistant and extensively drug-resistant Acinetobacter baumannii ventriculitis and meningitis: a literature review","volume":"41","author":"Karaiskos","year":"2013","journal-title":"Int. J. Antimicrob. Ag"},{"key":"10.1016\/j.ejps.2022.106266_bib0021","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/B978-0-444-53485-9.00028-3","article-title":"Cerebrospinal fluid flow in adults","volume":"135","author":"Bradley","year":"2016","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.ejps.2022.106266_bib0022","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s00228-017-2313-4","article-title":"Plasma and cerebrospinal fluid population pharmacokinetics of vancomycin in postoperative neurosurgical patients after combined intravenous and intraventricular administration","volume":"73","author":"Li","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2022.106266_bib0023","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/BF00165710","article-title":"Pharmacokinetics of intraventricular administration","volume":"1","author":"Collins","year":"1983","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.ejps.2022.106266_bib0024","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s12028-012-9784-z","article-title":"Systematic review of efficacy, pharmacokinetics, and administration of intraventricular vancomycin in adults","volume":"20","author":"Ng","year":"2012","journal-title":"Neurocrit. Care"},{"key":"10.1016\/j.ejps.2022.106266_bib0025","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/cid\/cir078","article-title":"Vancomycin: we can\u2019t get there from here","volume":"52","author":"Patel","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejps.2022.106266_bib0026","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1128\/AAC.42.10.2739","article-title":"In vitro studies of pharmacodynamic properties of vancomycin against staphylococcus aureus and staphylococcus epidermidis","volume":"42","author":"L\u00f6wdin","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2022.106266_bib0027","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/jac\/38.4.589","article-title":"The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of staphylococcus aureus under aerobic and anaerobic conditions","volume":"38","author":"Larsson","year":"1996","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejps.2022.106266_bib0028","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2165\/00003088-200443130-00005","article-title":"Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections","volume":"43","author":"Moise-Broder","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2022.106266_bib0029","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0891-5520(03)00065-5","article-title":"Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid","volume":"17","author":"Craig","year":"2003","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"10.1016\/j.ejps.2022.106266_bib0030","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrmicro862","article-title":"Antimicrobial pharmacodynamics: critical interactions of \u2018bug and drug","volume":"2","author":"Drusano","year":"2004","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejps.2022.106266_bib0031","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.ajic.2006.05.227","article-title":"Pharmacodynamics: relation to antimicrobial resistance","volume":"34","author":"Rybak","year":"2006","journal-title":"Am. J. Infect. Control"},{"key":"10.1016\/j.ejps.2022.106266_bib0032","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/jpids\/piaa057","volume":"9","author":"Rybak","year":"2020","journal-title":"J. Pediatric Infect. Dis. Soc."},{"key":"10.1016\/j.ejps.2022.106266_bib0033","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2147\/IDR.S109485","article-title":"Pharmacist-managed dose adjustment feedback using therapeutic drug monitoring of vancomycin was useful for patients with methicillin-resistant Staphylococcus aureus infections: a single institution experience","volume":"9","author":"Hirano","year":"2016","journal-title":"Infect. Drug Resist."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098722001518?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098722001518?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:03:10Z","timestamp":1760529790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098722001518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":33,"alternative-id":["S0928098722001518"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2022.106266","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Norvancomycin for the treatment of central nervous system MRSA infections: A randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2022.106266","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106266"}}